Skip to Main Content

Advertisement

Skip Nav Destination
Issue Cover
Current Issue
Volume 143,
Issue 9,
February 29 2024

Issue Highlights

Latest in Blood
Plenary Papers
Woosuk S. Hur; Tomohiro Kawano; Jean Marie N. Mwiza; David S. Paul; Robert H. Lee; Emily G. Clark; Emma G. Bouck; Ananya Dutta; Can Cai; Stephen R. Baker; Martin Guthold; Nigel Mackman; Pierre Mangin; Alisa S. Wolberg; Wolfgang Bergmeier; Matthew J. Flick
First Edition
Kyra J. Fuchs; Marian van de Meent; Maria W. Honders; Indu Khatri; Michel G.D. Kester; Eva A.S. Koster; Georgia Koutsoumpli; Arnoud H. de Ru; Cornelis A.M. Van Bergen; Peter A. van Veelen; Peter A.C. 't Hoen; Peter van Balen; Erik B van den Akker; Hendrik Veelken; Constantijn JM JM Halkes; J.H. Frederik Falkenburg; Marieke Griffioen
Clinical Trials and Observations
Reilly Allison; Emily Welby; Vanessa Ehlers; Anthony Burand, Jr; Olena Isaeva; Damaris D Nieves Torres; Janelle Highland; Amanda M. Brandow; Cheryl L Stucky; Allison D Ebert

Advertisement




Featured Content

Brentuximab vedotin plus dacarbazine or nivolumab in classical Hodgkin lymphoma; loss of CD20 causes resistance to mosunetuzumab in r/r B-cell lymphomas; trogocytosis as a driver of RBC antigen loss

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study

Trogocytosis drives red blood cell antigen loss in association with antibody-mediated immune suppression

How I Treat Series: Hematologic Complications in Pregnancy

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement